Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

contributed by Agilent | 05/15/2023

With the Agilent SureSelect Cancer CGP assay, a targeted, pan-cancer panel based on next-generation sequencing (NGS) technology, you’ll have access to the most clinically relevant and up-to-date biomarker content by detecting key classes of somatic alterations. Have confidence in high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimum sample input. The workflow solution is configurable to meet the needs of your lab with options to incorporate sample QC, automation, and data analysis solutions.

>> Download brochure as a PDF

Find out more on Agilent's website here

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Retina field I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.